BMO Capital Markets. "As the industry evolves, our priority is providing exceptional service to our clients while delivering more integrated and innovative solutions to grow our market leading ...

BMO Capital Markets. "As the industry evolves, our priority is providing exceptional service to our clients while delivering more integrated and innovative solutions to grow our market leading ...

Arvinas (NASDAQ:ARVN – Get Free Report)‘s stock had its “outperform” rating reiterated by BMO Capital Markets in a research report issued to clients and investors on Wednesday,Benzinga ...

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report ...

BMO Capital analyst Benjamin Pham maintained a Buy rating on Gibson Energy (GBNXF – Research Report) yesterday and set a price target of ...

Key themes to include the impact of global events on commodities and capital markets and the evolution of the sector. "For more than 100 years, BMO has been a global leader and trusted advisor ...

BMO Capital analyst John McNulty maintained a Buy rating on Chemours Company (CC – Research Report) yesterday and set a price target of $27.00.

On Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...

Tuesday, BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal ...

Tuesday, BMO Capital Markets highlighted the potential risks faced by Real Estate Investment Trusts (REITs) specializing in Skilled Nursing Facilities (SNFs) due to possible changes in Federal Medical ...

On Tuesday, BMO Capital Markets reaffirmed their Outperform rating on Beam Therapeutics Inc (NASDAQ:BEAM), with a steady price target of $57.00. Currently trading at $26.57, the stock appears ...